S
Seza A. Gulec
Researcher at FIU Herbert Wertheim College of Medicine
Publications - 99
Citations - 3240
Seza A. Gulec is an academic researcher from FIU Herbert Wertheim College of Medicine. The author has contributed to research in topics: Thyroid cancer & Gamma probe. The author has an hindex of 30, co-authored 97 publications receiving 3011 citations. Previous affiliations of Seza A. Gulec include Florida International University & University Medical Center New Orleans.
Papers
More filters
Journal ArticleDOI
2009 EANM parathyroid guidelines
Elif Hindié,Omer Ugur,David Fuster,Michael O'Doherty,Gaia Grassetto,Pablo Ureña,A. G. Kettle,Seza A. Gulec,Francesca Pons,Domenico Rubello +9 more
TL;DR: The present guidelines were issued by the Parathyroid Task Group of the European Association of Nuclear Medicine and the main focus was imaging of primary hyperparathyroidism, with aspects related to radio-guided surgery of hyperparathiroidism and imaging of chronic kidney disease patients with secondary hyperparethyroidism.
Journal Article
Preoperative Localization and Radioguided Parathyroid Surgery
Giuliano Mariani,Seza A. Gulec,Domenico Rubello,Giuseppe Boni,Marco Puccini,Maria Rosa Pelizzo,Gianpiero Manca,Dario Casara,Guido Sotti,Paola Anna Erba,Duccio Volterrani,Armando E. Giuliano +11 more
TL;DR: A gamma-probe-guided minimally invasive parathyroidectomy (MIP) has been made possible by the introduction of (99m)Tc-sestamibi scintigraphy for preoperative localization of parathy thyroid adenomas.
Journal ArticleDOI
Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors
Andrew S. Kennedy,Patrick McNeillie,William A. Dezarn,Charles W. Nutting,Bruno Sangro,Dan Wertman,Michael Garafalo,David M. Liu,Douglas Coldwell,Michael Savin,Tobias F. Jakobs,Steven C. Rose,Richard R.P. Warner,Dennis L. Carter,Stephen Sapareto,Subir Nag,Seza A. Gulec,Allison Calkins,Vanessa L. Gates,Riad Salem +19 more
TL;DR: There was an association between the empiric method, percentage of calculated activity delivered to the patient, and the most severe toxicity, RILD, and a predictive model for RILD is not yet possible.
Journal Article
Dosimetry-Guided Radioactive Iodine Treatment in Patients with Metastatic Differentiated Thyroid Cancer: Largest Safe Dose Using a Risk-Adapted Approach
TL;DR: Dosimetry-guided RAI treatment allows administration of the maximum possible RAI dose to achieve the maximum therapeutic benefit andimation of tumor dose rates helps to determine the curative versus the palliative intent of the therapy.
Journal Article
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
Chaitanya R. Divgi,Neil H. Bander,Neil H. Bander,Neil H. Bander,Andrew M. Scott,Andrew M. Scott,Joseph A. O'Donoghue,George Sgouros,Sydney Welt,Sydney Welt,Ronald D. Finn,Francesca Morrissey,Peter Capitelli,Jeanne M. Williams,Devie Deland,Aparna Nakhre,Egbert Oosterwijk,Egbert Oosterwijk,Seza A. Gulec,Martin C. Graham,Steven M. Larson,Lloyd J. Old,Lloyd J. Old +22 more
TL;DR: On the basis of external imaging, 131I-labeled mouse monoclonal antibody G250 showed excellent localization to all tumors that were > or =2 cm, and Hematological toxicity was correlated with whole-body absorbed radiation dose.